Key statistics
As of last trade, Ultragenyx Pharmaceutical Inc (0LIF:LSE) traded at 47.81, 28.35% above the 52 week low of 37.25 set on Jun 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 47.81 |
Low | 47.81 |
Bid | -- |
Offer | -- |
Previous close | 46.90 |
Average volume | 2.59k |
---|---|
Shares outstanding | 92.34m |
Free float | 89.00m |
P/E (TTM) | -- |
Market cap | 4.36bn USD |
EPS (TTM) | -6.46 USD |
Data delayed at least 20 minutes, as of Nov 25 2024 14:30 GMT.
More ▼
Announcements
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
- Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
- Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
- Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
- Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
- Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
- Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)
- Ultragenyx to Participate in Investor Conferences in September
- Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
More ▼